CDK4 and neoplasm: CDK4/6 inhibitors not only induce tumour cell cycle arrest but also promote anti‐tumour immunity, as they upregulate the expression of endogenous retroviral elements in tumour cells, producing increased intracellular levels of double‐stranded RNA, thereby stimulating the production of type III interferons, which in turn enhance tumour antigen presentation [100].